| 1.63 0.08 (5.16%) | 10-28 11:50 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.14  |
1-year : | 2.39 |
| Resists | First : | 1.83 |
Second : | 2.04 |
| Pivot price | 1.65 |
|||
| Supports | First : | 1.5 | Second : | 1.24 |
| MAs | MA(5) : | 1.56 |
MA(20) : | 1.7 |
| MA(100) : | 1.8 |
MA(250) : | 1.64 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 11.5 |
D(3) : | 12.5 |
| RSI | RSI(14): 35.7 |
|||
| 52-week | High : | 2.57 | Low : | 1.17 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ AUTL ] has closed above bottom band by 21.6%. Bollinger Bands are 22.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.55 - 1.56 | 1.56 - 1.57 |
| Low: | 1.48 - 1.5 | 1.5 - 1.51 |
| Close: | 1.51 - 1.53 | 1.53 - 1.54 |
Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Additionally, AUTO1/22 is in a Phase 1 study for pediatric patients experiencing relapsed or refractory ALL. Autolus is also advancing AUTO4, a programmed T cell therapy designed to target TRBC1 for the treatment of peripheral T-cell lymphoma, and AUTO8, a product candidate currently in Phase I clinical trials for multiple myeloma. In earlier development, AUTO6NG, a programmed T cell therapy, is in preclinical research targeting GD2 for neuroblastoma, and AUTO5 is another hematological product candidate in its preclinical stages. Established in 2014, Autolus Therapeutics maintains its headquarters in London, United Kingdom.
Tue, 27 Oct 2026
Autolus Therapeutics: Cheap On Sales, Still Far From Breakeven (NASDAQ:AUTL) - Seeking Alpha
Tue, 27 Oct 2026
Autolus Therapeutics: Key Questions For The Near Term - Seeking Alpha
Mon, 26 Oct 2026
Autolus Therapeutics to Report Third Quarter 2026 Financial Results and Host Conference Call on November 10, 2026 - The Manila Times
Fri, 23 Oct 2026
Autolus Therapeutics plc Estimates – NASDAQ:AUTL - TradingView
Mon, 05 Oct 2026
All You Need to Know About Autolus Therapeutics (AUTL) Rating Upgrade to Buy - Yahoo Finance
Thu, 20 Aug 2026
ARMISTICE CAPITAL, LLC Trims Autolus Therapeutics PLC (AUTL) Sta - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 266 (M) |
| Shares Float | 103 (M) |
| Held by Insiders | 18.5 (%) |
| Held by Institutions | 63.4 (%) |
| Shares Short | 8,400 (K) |
| Shares Short P.Month | 9,080 (K) |
| EPS | -1.06 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.28 |
| Profit Margin | -238.7 % |
| Operating Margin | -96 % |
| Return on Assets (ttm) | -25.5 % |
| Return on Equity (ttm) | -133 % |
| Qtrly Rev. Growth | 118.4 % |
| Gross Profit (p.s.) | -0.33 |
| Sales Per Share | 0.44 |
| EBITDA (p.s.) | -0.89 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -226 (M) |
| Levered Free Cash Flow | -201 (M) |
| PE Ratio | -1.47 |
| PEG Ratio | 0 |
| Price to Book value | 5.53 |
| Price to Sales | 3.51 |
| Price to Cash Flow | -1.83 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|